Central Asia Drug Action Programme (CADAP Phase 6) represents continuity of the EU policy and long term engagement with Central Asian partners to help further strengthen their national policies in drug demand reduction. The beneficiaries of CADAP 6 include policy makers, drug experts, penitentiary and hospital staff, media professionals, teachers, drug users, prisoners, young people and the general public.
-
This Component aims to enrich national authorities' knowledge about the EU balanced drugs policy and different national strategies implemented in the EU countries, and assist willing governments in CA with the review of old and drafting of new National Drugs Strategies, Action Plans and drug legislation.
-
This Component aims to support CA countries in acquiring a comprehensive approach of data collection and data supported decision and policy making, using as a model the standards of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). -
This Component aims to support all CA countries in their prevention programmes and actions employing European best practices and international standards. -
This Component aims to support CA countries in their treatment and harm reduction programmes and actions employing European best practices and international standards.
-
26.02.2022
-
16.02.2022
Within framework of CADAP 6, Germany contributes to the EU policy in the region in supporting third countries’ efforts to deal with the challenges to public health, safety and security. Since 2010, Germany has been supporting CADAP in taking over the coordinating and steering role of the programme. CADAP 6, which took force in April 2015, will continue building on the results of preceding phases by investing in capacity building and professional skills upgrading of drug related ministries, state agencies, rehabilitation centers and other key stakeholders, while promoting and further advocating for the institutionalized application of good European practices.
